MDNews - Cleveland-Akron-Canton

November/December 2015

Issue link: http://viewer.e-digitaledition.com/i/589857

Contents of this Issue

Navigation

Page 26 of 43

DR. JEREMY RICH RECEIVES NCI'S OUTSTANDING INVESTIGATOR AWARD Jeremy Rich, MD HEALTHCARE ADVOCATES, INDUSTRY LEADERS With more than 40 years of experience, our Healthcare Section offers Healthcare Representation & Counseling, Coding Review and Staff Training. We make it possible for you to focus on patient care, while we tackle the legal obstacles you are faced with on an ongoing basis. WE ARE THE HEALTHCARE SECTION OF KRUGLIAK, WILKINS, GRIFFITHS & DOUGHERTY, CO., L.P.A. 4775 Munson Street N.W. | P.O. Box 36963 | Canton, Ohio 44735 | 330-497-0700 | Fax 330-497-4020 John M. Tucker • Randall C. Hunt • Fred J. Haupt Jason F. Haupt • Laura A. Brady Offices in Canton, Akron, Alliance, New Philadelphia & Sugarcreek KWGD.com LOCAL DOC IN NATIONAL NEWS J E R E M Y R I C H , M D, Chair of t he D epa r t ment of Stem Cell Biology & Regenerative Medicine in Cleveland Clinic's Lerner Research Institute, has been awarded the National Cancer Institute's prestigious Outstanding Investigator Award and will receive $6.7 million over seven years for his research labora- tory. The National Cancer Institute awards these select grants to established scientists who have exceptional records of accomplishment and whose research shows great promise for future medical breakthroughs. "This is an amazing honor and opportunity," Dr. Rich says. "We are just now beginning to comprehend the unique biology of brain cancer stem cells, and this substantial award will push us years ahead in finding new treatments for glioblastoma." Dr. Rich is a well-known expert in the study of brain cancer stem cells, the self-renewing cells that are highly resistant to conventional cancer therapies. Brain cancer stem cells are believed to be responsible for the aggressive nature of glioblastoma, the most common and most lethal form of brain cancer. Dr. Rich's research, entitled "Dynamic Complexity of Brain Tumor Stem Cells," will focus on how brain cancer stem cells regulate their metabolism distinct from other cancer cells and stem cells in the brain. Understanding these mechanisms is expected to identify new methods to effectively eliminate the deadly stem cells. Dr. Rich was recruited to Cleveland Clinic in 2008 to lead its newly formed Department of Stem Cell Biology & Regenerative Medicine. "Dr. Rich is highly deserving of this award. He has made multiple, high-impact advances in our knowledge of what defines brain cancer stem cells and how they function," says Thomas Hamilton, PhD, Interim Chair of the Lerner Research Institute. "In addition to running his own very productive laboratory, he is building an impressive, multidisciplinary stem cell research department at Cleveland Clinic." ■

Articles in this issue

Links on this page

Archives of this issue

view archives of MDNews - Cleveland-Akron-Canton - November/December 2015